dc.creator | Duncan, Christopher J.A. | |
dc.creator | Randall, Richard E. | |
dc.creator | Hambleton, Sophie | |
dc.date.accessioned | 2020-09-25T20:38:12Z | |
dc.date.accessioned | 2022-09-23T18:05:59Z | |
dc.date.available | 2020-09-25T20:38:12Z | |
dc.date.available | 2022-09-23T18:05:59Z | |
dc.date.created | 2020-09-25T20:38:12Z | |
dc.identifier | 1362-4555 | |
dc.identifier | https://doi.org/10.1016/j.tig.2020.08.017 | |
dc.identifier | http://hdl.handle.net/20.500.12010/13831 | |
dc.identifier | https://doi.org/10.1016/j.tig.2020.08.017 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/3495157 | |
dc.description.abstract | The concept that type I interferons (IFN-I) are essential to antiviral immunity
derives from studies on animal models and cell lines. Virtually all pathogenic
viruses have evolved countermeasures to IFN-I restriction, and genetic loss
of viral IFN-I antagonists leads to virus attenuation. But just how important is
IFN-I to antiviral defence in humans? The recent discovery of genetic defects
of IFN-I signalling illuminates this and other questions of IFN biology, including
the role of the mucosa-restricted type III IFNs (IFN-III), informing our understanding
of the place of the IFN system within the concerted antiviral response. Here
we review monogenic lesions of IFN-I signalling pathways and summarise the
organising principles which emerge. | |
dc.language | eng | |
dc.publisher | Trends in genetics | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.rights | Abierto (Texto Completo) | |
dc.source | reponame:Expeditio Repositorio Institucional UJTL | |
dc.source | instname:Universidad de Bogotá Jorge Tadeo Lozano | |
dc.subject | Human antiviral immunity | |
dc.subject | Genetic lesions | |
dc.title | Genetic lesions of type i interferon signalling in human antiviral immunity | |